Inflammatory genital conditions

1. GLP-1 receptor agonists lower the risk of inflammatory genital conditions in humans (12.19% vs 18.65%; OR 0.605, 95% CI 0.504–0.727).

   “inflammatory genital infections (12.19% vs 18.65%; OR 0.605, 95% CI 0.504–0.727, p < 0.0001)”

   Humansin non-diabetic postpartum womenfemalesn = 5,387

   Association Between GLP-1 Receptor Agonist Use and Postpartum Pelvic Complications: A Global Matched Cohort Study

   Research Square·20 Aug 2026Preprint

More on GLP-1 receptor agonists